Roble, Belko & Company, Inc Mirum Pharmaceuticals, Inc. Transaction History
Roble, Belko & Company, Inc
- $629 Million
- Q4 2024
A detailed history of Roble, Belko & Company, Inc transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Roble, Belko & Company, Inc holds 19 shares of MIRM stock, worth $922. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19Holding current value
$922% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MIRM
# of Institutions
194Shares Held
54.1MCall Options Held
177KPut Options Held
167K-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.57MShares$319 Million13.79% of portfolio
-
Janus Henderson Group PLC London, X04.48MShares$217 Million0.09% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.45MShares$167 Million2.37% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$157 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA3.08MShares$149 Million3.81% of portfolio
About Mirum Pharmaceuticals, Inc.
- Ticker MIRM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,751,700
- Market Cap $1.78B
- Description
- Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...